TRV734
| Clinical data | |
|---|---|
| Other names | TRV-734 |
| Routes of administration | Oral[1][2][3] |
| Drug class | μ-Opioid receptor biased agonist; Analgesic |
| Pharmacokinetic data | |
| Elimination half-life | 1.9–2.5 hours[3] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C22H28FN3O |
| Molar mass | 369.484 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
TRV734 is a drug developed by Trevena, Inc. which acts as a biased agonist at the μ-opioid receptor, selective for activation of the G protein signaling pathway over β-arrestin 2 recruitment. It is closely related to oliceridine (TRV130) and has a similar pharmacological profile, but unlike oliceridine which has to be injected, TRV734 is suitable to be administered orally.[2][3] The drug reached phase 2 clinical trials for treatment of pain but was discontinued for this indication.[1][4] It is also under development for treatment of opioid-related disorders, in association with the National Institute on Drug Abuse (NIDA) and having reached phase 1 trials for this use, but no recent development has been reported.[1][4]
See also
References
- ^ a b c "TRV 734". AdisInsight. 28 March 2025. Retrieved 1 January 2026.
- ^ a b James IE, Skobieranda F, Soergel DG, Ramos KA, Ruff D, Fossler MJ (February 2020). "A First-in-Human Clinical Study With TRV734, an Orally Bioavailable G-Protein-Biased Ligand at the μ-Opioid Receptor". Clinical Pharmacology in Drug Development. 9 (2): 256–266. doi:10.1002/cpdd.721. PMID 31286645. S2CID 195843184.
- ^ a b c Ramos KA, James IE, Skobieranda F, Soergel DG, Ruff D, Fossler MJ (January 2022). "Two-Part Phase 1 Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy Adults". Clin Pharmacol Drug Dev. 11 (1): 51–62. doi:10.1002/cpdd.1016. PMID 34480428.
- ^ a b "Delving into the Latest Updates on TRV-734 with Synapse". Synapse. 14 October 2025. Retrieved 1 January 2026.